As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to the U.S. Congress in December 2021 about the H.R.6000, Cures 2.0 Act can be found below.
As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to the U.S. Congress in December 2021 about the H.R.6000, Cures 2.0 Act can be found below.